Innate Pharma S.A.
IPH.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.24 | 2.55 | 0.17 |
| FCF Yield | -6.20% | -21.87% | -10.12% | -22.06% |
| EV / EBITDA | -1.61 | -70.10 | -2.59 | -4.89 |
| Quality | ||||
| ROIC | -51.45% | -8.25% | -14.61% | -21.90% |
| Gross Margin | -252.41% | 10.83% | 12.11% | -288.08% |
| Cash Conversion Ratio | 0.14 | 4.30 | 0.33 | 1.11 |
| Growth | ||||
| Revenue 3-Year CAGR | -36.65% | 62.43% | -10.73% | -44.00% |
| Free Cash Flow Growth | 79.13% | -72.17% | 66.09% | 5.23% |
| Safety | ||||
| Net Debt / EBITDA | 0.69 | 16.70 | 0.68 | 1.38 |
| Interest Coverage | -12.97 | -19.80 | -85.52 | -153.29 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 31.38 | 271.16 | 131.61 | 291.64 |